// App-Quantinova.ai

2571 : Anti-Leukemic Activity of a Novel Pegylated Recombinant Erwinia Chrysanthemi-Derived L-Asparaginase On Lymphoid Cell Lines and Leukemia-Bearing Mouse Models.

Researchers

Presenter

  • Celine Lebeux

Principal Investigators

  • Nicolas Rachinel

  • Gilles Salles

  • Soraya Allas

  • Diane L Rossi

  • Pierre Sahakian

  • Michel Julien

  • Claire Lacroix

  • Thierry Abribat

Medical Centers

  • Universite Claude Bernard Lyon , CNRS UMR ENS HCL, Faculte de Medecine Lyon Sud., Oullins, France

  • Hematologie UMR CNRS, Centre Hospitalier Universitaire Lyon-Sud, Lyon, France

  • Alize Pharma, cully, France

  • Universite Claude Bernard Lyon , CNRS UMR ENS HCL, Faculte de Medecine Lyon Sud., Oullins, France

  • Alize Pharma, cully, France

Locations

  • France

Companies

  • Alize Pharma

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Lymphomas

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Erwinase

  • Asparaginase

  • Efaproxiral

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved